Atelerix receives Innovate UK grant for cell therapy preservation hydrogel
Biotechnology | Finance | Research
The hydrogel tech increases shelf-life between 4°C and 25°C, increasing treatment flexibility as well as widening manufacturing options and driving down cost
Atelerix has been awarded a grant of £267,000 from Innovate UK. The grant will be used to develop gel stabilisation technologies, developed by Atelerix, with the first objective of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature.
The project will initially focus on developing a stabilisation technology for REX-001, regenerative medicine company, Rexgenero's, lead development candidate, but is expected to have broad applicability to a wide range of other cell therapies. The project will benefit from additional expertise and experience provided by the Cell and Gene Therapy Catapult.
The UK-based company has also recently closed a £700,000 funding round.
Patented technology
Atelerix's patented technology enables the storage and transport of human cells at temperatures between 4°C and 25°C, preserving and extending their functional viability from days to weeks. The technology encapsulates cells in a natural hydrogel for safe shipment and storage. The cells can be recovered when needed by the addition of a gentle, cell-friendly buffer.
REX-001 consists of bone marrow-derived white blood cells extracted from a patient's own bone marrow (autologous). Extending the shelf-life of REX-001 will provide increased flexibility for transportation to and from the hospital and facilitate use for physicians treating patients with CLI.
Joe Dupere, CEO of Rexgenero, said: "Extending the shelf-life of our REX-001 autologous cell therapy is important to ensure that hospitals have the flexibility for less rigid scheduling of operating theatres, making it easier to treat patients and therefore enabling as many patients as possible to be treated with this novel, potentially curative therapy. Room temperature storage and transportation also widens our manufacturing options and should help to drive down cost."
Dr Mick McLean, CEO of Atelerix, added: "We're excited to be part of this collaboration with Rexgenero and the team at the Cell and Gene Therapy Catapult, and we deeply appreciate the support of Innovate UK to bring us together for this important project. The critical logistics of getting viable cell therapies to the patient are often overlooked and extending the shelf life of therapies such as REX-001 at room temperature would open up an entirely new approach for this sector."
Atelerix
ManChem funding roundup
Eli Lilly makes $1.1bn biopharma acquisition
Hospital moves in on manufacturing market
Gene modulation newcomer recieves $667,000 for proof of concept
BioLife Solutions makes acquisition for cryogenic equipment
Mesa Labs acquires Gyros Protein Technologies
Cesca Therapeutics changes name to match new focus
NGen contributes to C$4.2m Canadian viral vector manufacturing project
Bayer strengthens cell and gene therapies with BlueRock acquisition
Chr. Hansen and Lonza joint venture: Ready for contract manufacturing
Ex-FDA Commissioner returns to old venture capitalist firm
Related Product News
Tufts CSDD shows multi-million dollar benefits of Translational Pharmaceutics
Blackstone and Novartis: Joint venture targets cardiovascular disease
Lonza buys majority stake in Octane Biotech
WCG expands portfolio to include drug safety solution provider
About HPCi Media
About Manufacturing Chemist